Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAREON-NEC-1
jRCT2071260019Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- May 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial in extrapulmonary neuroendocrine carcinoma (EPNEC) comparing Obrixtamig + carboplatin + etoposide with Carboplatin + etoposide (2 arms). Primary endpoint: Overall survival. Started May 2026; status: recruiting.
02
Drugs
obrixtamigcarboplatinetoposide
03
Conditions
extrapulmonary neuroendocrine carcinoma (EPNEC)
Beyond the preview
Go deeper on jRCT2071260019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260019.